Understanding the ABCDS™ Framework

Course Overview

The ABCDS™ Framework organizes androgen care around the systems that actually determine long-term outcomes rather than the laboratory values that are easiest to follow. ABCDS™ should be applied during diagnosis, history and physical, and ongoing management, not just longitudinal monitoring. It addresses a recurring problem in testosterone and anabolic steroid medicine, where clinicians can track hormones closely while missing the physiologic processes that drive stroke, myocardial infarction, kidney disease, erectile dysfunction, iron depletion, and delayed cancer diagnosis. In this structure, A represents glycemic control, B represents blood pressure and kidney health, C represents cholesterol and cardiovascular disease, D represents iron balance and androgen-induced erythrocytosis, and S represents screening and total health surveillance. [1-8]

The framework becomes most useful at the exact moment the visit feels successful. Symptom improvement, better performance, or a more satisfying testosterone level can narrow clinical focus and shift attention away from broader risk. That is when underlying disease processes are most likely to progress unnoticed.

Learning Objectives

After completing this course, clinicians should be able to:

➀ Explain the purpose of the ABCDS™ Framework and why it is foundational to structured androgen medicine.

➁ Apply the A, B, C, D, and S domains to patients on testosterone therapy, anabolic steroids, or other androgen exposure.

➂ Use glycemic, renal, blood pressure, lipid, hematologic, and screening data together rather than in isolation.

➃ Distinguish androgen-induced erythrocytosis from myeloproliferative disease and recognize the risks of over-phlebotomy.

➄ Integrate ABCDS™ into diagnosis, monitoring, and long-term management of men and women receiving androgen-related care.

Course Topics

The following topics will be covered in the course text, video, diagrams or downloadable documents:

➀ Why ABCDS™ Matters in Androgen Medicine

➁ A — Glycemic Control

➂ B — Blood Pressure and Kidney Health

➃ C — Cholesterol and Cardiovascular Disease

➄ D — Iron Balance and Androgen-Induced Erythrocytosis

➅ S — Screening and Total Health Surveillance

➆ ABCDS™ in Patients on Testosterone Therapy

➇ ABCDS™ in Patients on Anabolic Steroids and Other High-Dose Androgens

➈ Common Errors in ABCDS™ Application

➉ Clinical Integration and Closing Logic

Video Lesson Takeaways

◉ ABCDS™ exists to stop clinicians from mistaking hormone follow-up for complete medical care.

◉ A patient can feel better on testosterone and still be drifting toward kidney disease, vascular disease, or missed screening if the rest of the physiology is not being watched closely.

◉ Glycemic control deserves early attention because once that part of the case starts slipping, the rest of the risk profile usually gets harder to control.

◉ Blood pressure is not being taken seriously enough when it is documented without asking what it may already be doing to the kidneys.

◉ Lipid review becomes much more meaningful when the clinician stops asking whether the numbers look acceptable and starts asking what the arteries are actually experiencing.

◉ Testosterone-related erythrocytosis should be approached as a secondary red-cell problem, not reflexively treated like a primary hematologic disease.

◉ Repeated phlebotomy can make a patient look “managed” on paper while iron depletion and the original driver of the hematocrit rise are both getting worse.

◉ Screening is easy to neglect in patients who are seen often for hormone care, which is exactly why it has to stay visible on purpose.

◉ The framework is most useful when the patient seems to be doing well, because that is when clinicians are most likely to miss the quieter risks building in the background.

◉ Missing one letter in ABCDS™ can mean missing the part of the case most likely to harm the patient next.

➀ Why ABCDS™ Matters in Androgen Medicine

Androgen medicine is especially prone to false reassurance. Patients are followed regularly, laboratory values are reviewed, treatment is adjusted, and symptoms often improve, creating the impression of strong care. However, physiologic risk can progress in parallel. A patient may feel better, perform better, and look better while blood pressure worsens, albuminuria develops, ApoB remains untreated, or iron depletion occurs after serial phlebotomy. Stroke risk, kidney disease, progressive vascular injury, and delayed cancer diagnosis do not pause simply because testosterone is being monitored closely. This is the clinical moment where a narrower approach fails and ABCDS™ becomes essential. [1-8]

The problem clinicians encounter is prioritization. Testosterone, estradiol, and hematocrit are visible, familiar, and easy to revisit, while glycemic dysregulation, albuminuria, arterial risk, and lapsed surveillance require more deliberate attention. ABCDS™ corrects this by forcing the clinician back into an internal medicine mindset and asking a single question: what is most likely to injure the patient next if nothing changes?

➁ A — Glycemic Control

A stands for glycemic control, and in practice it begins with hemoglobin A1C and fasting glucose. The A1C reflects average glycemic control over roughly three months, while fasting glucose offers a real-time glycemic snapshot. Together they identify prediabetes, impaired fasting glucose, and type 2 diabetes. Current ADA Standards of Care continue to recognize these measures as core tools for diagnosis and classification. [1]

What makes A so important in androgen medicine is how easily it is underestimated. Many patients do not look like the stereotype of diabetes risk. They may be muscular, physically active, highly engaged in health behavior, or deeply invested in body composition. That appearance can mislead clinicians into assuming metabolic stability. Insulin resistance, poor diet quality, visceral adiposity, sleep disruption, and early glycemic deterioration remain common in precisely the patients who appear externally disciplined.

Glycemic dysfunction contributes directly to myocardial infarction, stroke, chronic kidney disease, peripheral vascular disease, and erectile dysfunction. It also distorts symptom interpretation. Fatigue, poor recovery, worsening sexual function, and flattening well-being may be framed as a hormone problem when the larger physiologic driver is metabolic decline. [1]

➂ B — Blood Pressure and Kidney Health

B links blood pressure to kidney health because hypertension without kidney evaluation is incomplete medicine. Blood pressure is not simply a number to record and revisit later. It is a central driver of stroke, myocardial infarction, heart failure, chronic kidney disease, and erectile dysfunction, and it can remain clinically quiet for years while meaningful vascular injury accumulates. [2,3]

That is why measurement alone is not enough. Blood pressure assessment should rely on reproducible home or ambulatory measurements (ABPM) rather than isolated in-office readings [2]. Significant inter-arm blood pressure differences may indicate underlying vascular pathology and require further evaluation. In a population receiving testosterone or exposed to anabolic steroids, those data become far more useful when paired with renal evaluation through eGFR and urine albumin-creatinine ratio. Creatinine-based eGFR may be falsely abnormal in muscular patients or those using creatine, requiring confirmatory testing such as cystatin C. Urinalysis and albuminuria screening are essential components of kidney evaluation, particularly in hypertensive or androgen-exposed patients [3].

A mildly elevated blood pressure may be acknowledged and then overshadowed by dose discussions, hormone symptoms, or laboratory review. No home values are checked. No albuminuria is assessed. No one asks whether sleep apnea, stimulant exposure, obesity, fluid retention, or androgen exposure is intensifying the physiology [2]. In that setting the clinician has not really evaluated B. They have only noticed it.

Patients rarely present saying they are worried about the long-term vascular consequences of rising pressure. They come in worried about libido, fatigue, and performance. A good clinician uses B to widen the frame and show that early erectile decline, exercise intolerance, headaches, and subtle changes in well-being may have a vascular and renal story behind them long before the patient becomes overtly ill.

➃ C — Cholesterol and Cardiovascular Disease

C stands for cholesterol and cardiovascular disease. Cardiovascular disease remains the leading global cause of death, and in many patients it represents the cumulative endpoint of years of poorly controlled A and B. [4]

Core laboratory markers include LDL cholesterol and ApoB. Modern cardiovascular assessment is increasingly particle-aware and risk-context aware rather than dependent on a single cholesterol value. [4,5] A patient with modestly abnormal routine lipids may still carry far more risk than the panel suggests when obesity, diabetes, family history, elevated ApoB, hypertension, prior anabolic exposure, or vascular symptoms are present. This is where casual reassurance becomes dangerous.

Anatomical evaluation using coronary artery calcium scoring or CT angiography can reveal disease not apparent from lipid values alone. Once disease is present, the conversation changes. The task is no longer to admire whether the cholesterol profile is “not terrible.” The task is to lower risk aggressively enough to match the anatomy that is already there. Early anatomical screening of coronary arteries may be considered in selected patients based on age and risk profile [6].

A frequent clinical mistake under C is allowing an acceptable-looking LDL to quiet the rest of the cardiovascular conversation [4,5]. That is particularly weak medicine in patients whose overall profile clearly places them in a higher-risk category. Another mistake is turning testosterone into either the complete explanation or the complete excuse. Some patients do experience androgen-related lipid effects. Others bring preexisting genetic or metabolic risk into treatment. The clinician’s responsibility is to identify the risk that is actually present and manage it with appropriate intensity, not with whichever explanation feels most convenient.

➄ D — Iron Balance and Androgen-Induced Erythrocytosis

D stands for iron balance and androgen-induced erythrocytosis. This domain separates structured androgen medicine from assembly-line protocol care because it forces the clinician to distinguish visible laboratory change from correct interpretation. Androgen-induced erythrocytosis is generally a secondary red-cell process, not polycythemia vera, and the workup and management should reflect that difference. Erythrocytosis is influenced by genetics, hypoxia, sleep apnea, altitude, and other physiologic factors in addition to androgen exposure. [7,8]

Erythrocytosis is common enough in testosterone therapy that clinicians often fall into suboptimal responses: stop therapy, donate blood, resume therapy, repeat. Excessive phlebotomy can lead to iron depletion and may paradoxically worsen the erythrocytosis cycle over time. Current literature continues to question whether routine phlebotomy without stronger reasoning improves the outcomes clinicians think they are protecting. [8]

Once erythrocytosis develops or phlebotomy is repeated, a CBC alone is no longer enough. Ferritin and broader iron studies become essential because the clinician otherwise has no clear sense of whether the patient is maintaining iron balance, drifting toward depletion, or being repeatedly corrected without understanding why the red-cell rise is happening in the first place. D forces you to ask why the hematocrit is rising and what will the chosen intervention cost them if repeated over time. [8]

➅ S — Screening and Total Health Surveillance

S stands for screening and total health surveillance. Patients on androgens still require age-appropriate and risk-appropriate screening [9-11]. Colorectal, prostate, breast cancers, and other risk-based evaluations appropriate to age, sex, and overall clinical context still have to be kept visible. [9-11] In long-term hormone management, they often are not. Screening should also include organ-specific evaluation such as gastrointestinal, dermatologic, and cardiopulmonary risk based on patient history. Failure to appropriately monitor PSA in men on androgens may carry significant medico-legal risk if prostate pathology is missed.

As the patient ages, accumulates risk, and continues living in a broader primary-care reality, the conversation keeps circling back to testosterone, estradiol, and subjective response. If screening is assumed rather than verified, the chart can remain busy while the patient drifts further from true preventive care.

➆ ABCDS™ in Patients on Testosterone Therapy

In patients receiving testosterone therapy, ABCDS™ should function as a continuous monitoring framework rather than a baseline screening tool that fades once treatment begins. The patient feels better, the hormone numbers look better, and follow-up gradually contracts around those visible gains.

A patient with improving energy and libido but worsening A, B, C, D, or S markers is not actually well managed. ABCDS™ forces the clinician to revisit the systems most likely to determine whether the patient remains healthy enough to benefit from therapy over years rather than just months [1-8].

➇ ABCDS™ in Patients on Anabolic Steroids and Other High-Dose Androgens

In high-dose androgen users, ABCDS™ becomes even more important because risk is amplified, disclosure may be incomplete, and superficial improvement is especially misleading. Patients in this category often look resilient and motivated, which can tempt clinicians to underweight the physiologic burden building underneath that appearance. Blood pressure, kidney strain, atherogenic risk, erythrocytosis, and screening neglect may all be advancing in parallel while the visible conversation stays centered on compounds, dosing, or performance effects [2-8]. A patient can leave feeling informed about androgen exposure and still remain dangerously uninformed about stroke risk, CKD, iron depletion, or overdue screening if the clinician does not use ABCDS™ to widen the frame.

➈ Common Errors in ABCDS™ Application

Many outcomes blamed on testosterone are actually failures in A, B, C, or D. The hormone is visible, so it gets blamed. The neglected system is less visible, so it gets missed. Glycemic disease goes underrecognized. Albuminuria is not checked. Cardiovascular risk is softened into casual lipid review. Erythrocytosis is handled reflexively. Screening is assumed to be someone else’s job [1-8].

Another recurring error is diffusion of responsibility. The endocrinologist assumes primary care is managing it. Primary care assumes the specialist will catch it. The patient assumes everyone is communicating. ABCDS™ is strongest when it cuts through that vagueness and makes the clinician ask, explicitly, which part of the risk picture is actually being handled and which part is simply being assumed away.

➉ Clinical Integration and Closing Logic

The framework can be applied rapidly in clinical encounters by systematically reviewing each domain in sequence during every visit. A patient maintaining a satisfactory testosterone level while experiencing worsening markers in the A, B, C, D, or S domains is not well-managed; conversely, a patient with ideal cardiometabolic control who still suffers from unresolved symptomatic androgen deficiency requires further endocrine refinement. [1-8]

If hormones are tracked while systemic risk is ignored, the clinician is managing numbers instead of a human being.

Symptom response often creates a dangerous form of false reassurance. A patient frequently reports improved libido, higher energy, and better performance even as blood pressure rises [2], albuminuria emerges [3], or repeated phlebotomy induces iron depletion [8]. In these instances, the "success" of the hormonal intervention masks a medical failure. [1-8]

The ABCDS™ framework shifts the primary question from "Is the hormone plan working?" to "Is the patient becoming safer over time?" While this is a more demanding standard, it is the only one that accurately predicts long-term outcomes. If a single letter is omitted from the clinical visit, the patient's actual risk profile can disappear along with it. [1-8]

COURSE SUMMARY

The ABCDS™ Framework gives clinicians a fast, repeatable structure for identifying the disease drivers that most often determine long-term outcomes in patients on testosterone and anabolic steroids.

Used correctly, ABCDS™ changes what the clinician notices, what gets prioritized first, and what gets protected over time. It keeps hormone care anchored to internal medicine instead of allowing testosterone levels, symptom response, or hematocrit alone to dominate the case.

REFERENCES

American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(suppl 1):S27-S49.
Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. J Am Coll Cardiol. 2025;86(18):1567-1678.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018.
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-3209. doi:10.1016/j.jacc.2018.11.002
Reyes-Soffer G, Ginsberg HN, Berglund L, et al. Lipoprotein(a): A genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease. Arterioscler Thromb Vasc Biol. 2022;42:e48-e60.
Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary artery calcium scoring. J Am Coll Cardiol. 2007;49(18):1860-1870.
Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and management of testosterone deficiency: American Urological Association guideline. J Urol. 2018;200(2):423-432.
Bond P, Verdegaal T, Smit DL. Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?. Endocr Connect. 2024;13(10):e240283. Published 2024 Sep 28. doi:10.1530/EC-24-0283.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer Early Detection. Version 2.2026. February 18, 2026.
US Preventive Services Task Force. Colorectal cancer: screening. JAMA. 2021;325(19):1965-1977.
US Preventive Services Task Force. Breast cancer: screening. JAMA. 2024;331(22):1916-1925.

ABCDS™ Framework: A Structured Internal Medicine System for Patients on Testosterone and Anabolic Steroids

Course Overview

Learning Objectives

Course Topics

009 ABCDS™ Framework: A Structured Internal Medicine System for Patients on Testosterone and Anabolic Steroids

Video Lesson Takeaways

➀ Why ABCDS™ Matters in Androgen Medicine

➁ A — Glycemic Control

➂ B — Blood Pressure and Kidney Health

➃ C — Cholesterol and Cardiovascular Disease

➄ D — Iron Balance and Androgen-Induced Erythrocytosis

➅ S — Screening and Total Health Surveillance

➆ ABCDS™ in Patients on Testosterone Therapy

➇ ABCDS™ in Patients on Anabolic Steroids and Other High-Dose Androgens

➈ Common Errors in ABCDS™ Application

➉ Clinical Integration and Closing Logic

Recommended Grand Rounds Case Reviews

Advanced Clinical Training Insights